The current stock price of SRDX is 42.98 USD. In the past month the price increased by 52.95%. In the past year, price increased by 9.28%.
ChartMill assigns a technical rating of 7 / 10 to SRDX. When comparing the yearly performance of all stocks, SRDX is one of the better performing stocks in the market, outperforming 77.51% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to SRDX. While SRDX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SRDX reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS decreased by -172.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.38% | ||
| ROE | -15.84% | ||
| Debt/Equity | 0.27 |
7 analysts have analysed SRDX and the average price target is 43.86 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 42.98.
For the next year, analysts expect an EPS growth of 10.36% and a revenue growth -4.48% for SRDX
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.02 | 188.146B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.95 | 169.625B | ||
| SYK | STRYKER CORP | 23.97 | 137.924B | ||
| BSX | BOSTON SCIENTIFIC CORP | 22.17 | 111.924B | ||
| BDX | BECTON DICKINSON AND CO | 13.75 | 59.33B | ||
| IDXX | IDEXX LABORATORIES INC | 43.44 | 51.339B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.38 | 46.291B | ||
| RMD | RESMED INC | 21.75 | 38.394B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.39 | 37.64B | ||
| DXCM | DEXCOM INC | 27.76 | 27.621B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The company also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
SURMODICS INC
9924 W 74th St
Eden Prairie MINNESOTA 55344 US
CEO: Gary R. Maharaj
Employees: 389
Phone: 19525007000
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The company also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
The current stock price of SRDX is 42.98 USD. The price increased by 0.35% in the last trading session.
SRDX does not pay a dividend.
SRDX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
SURMODICS INC (SRDX) currently has 389 employees.
You can find the ownership structure of SURMODICS INC (SRDX) on the Ownership tab.